A detailed history of Sherbrooke Park Advisers LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 19,719 shares of VIR stock, worth $145,526. This represents 0.03% of its overall portfolio holdings.

Number of Shares
19,719
Holding current value
$145,526
% of portfolio
0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $143,159 - $210,993
19,719 New
19,719 $148 Million
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $96,253 - $259,273
10,531 New
10,531 $98.7 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.